In a preclinical model of human breast cancer, bisphosphonate treatment (zoledronate or risedronate) of immunodeficient animals promotes the accumulation of human Vγ9Vδ2 T cells in tumor xenografts producing high IPP levels, which leads to tumor regression [27,28]. Here, IPP is linked to neoplasm.